Brief: Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial
07/11/2022 14:01
Nov 7 (Reuters) - Vaccitech PLC VACC.O :
* VACCITECH PROVIDES UPDATE ON ONGOING VTP-300 PHASE 1B/2A
TRIAL
SHOWING SUSTAINED REDUCTIONS OF HBSAG IN PATIENTS WITH CHRONIC
HEPATITIS B
* VACCITECH - VTP-300 INDUCED SUSTAINED REDUCTIONS OF
HEPATITIS B
SURFACE ANTIGEN IN PEOPLE WITH CHRONIC HEPATITIS B DURING
ONGOING PHASE 1B/2A TRIAL
* VACCITECH PLC- NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
AND
INFREQUENT TRANSIENT TRANSAMINITIS, AS OF 28 SEPTEMBER 2022
Source text for Eikon: ID:nGNXb9BC05
Further company coverage: VACC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing